SAN JOSE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company’s management team will participate in three upcoming conferences. These conferences include:
UBS Global Healthcare Conference
Location: Terranea Resort, Rancho Palos Verdes, CA
Date: Thursday, November 14, 2024 at 10:15am PT
Format: Fireside Chat and 1x1 Meetings
Stifel Healthcare Conference
Location: Lotte New York Palace Hotel, New York, NY
Date: Monday, November 18, 2024 at 4:10pm ET
Format: Fireside Chat and 1x1 Meetings
7th Annual Evercore ISI HealthCONx Conference
Location: The Loews Coral Gables Hotel, Coral Gables, FL
Date: Wednesday, December 4, 2024 at 12:55pm ET
Format: Fireside Chat and 1x1 Meetings
Interested parties can register for and access the live webcasts for these conferences by visiting the “Events” section of the Rani Therapeutics website. The webcast replays will be available after the conclusion of the respective presentations.
About Rani Therapeutics
Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® capsule technology. For more information, visit ranitherapeutics.com.
Investor Contact:
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$1.53 |
Daily Change: | 0.07 4.45 |
Daily Volume: | 1,098,532 |
Market Cap: | US$50.800M |
November 14, 2024 October 17, 2024 August 06, 2024 June 24, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB